After nearly two years of waiting, the Federal Government has released its official response to the Senate inquiry into equitable access to diagnosis and treatment for rare and less common cancers, including neuroendocrine cancer.
Patients say Government’s rare cancer inquiry response falls short of needed action
September 1, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News
